Wockhardt gets US FDA tentative approval for Olopatadine

01 Jul 2011 Evaluate

Drug firm Wockhardt has received tentative approval from US Food and Drug Administration (USFDA) for marketing 0.1% solution of Olopatadine hydrochloride eye drops, which is used for allergic conjunctivitis. Olopatadine is the generic name for the brand Patanol, marketed in the US by Alcon laboratories Inc, now a subsidiary of Novartis AG.

The patent covering this product is under litigation in the US courts and Wockhardt will launch the product after resolution of the same.

Wockhardt is a global, pharmaceutical and biotechnology company that has grown by leveraging two powerful trends impacting the world of medicine - globalization and biotechnology. The company has a market capitalization of over $1 billion and an annual turnover of $650 million.

Wockhardt Share Price

1363.15 12.80 (0.95%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×